Meeting
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
Authors
Dawei Chen
Shandong Cancer Hospital, Shandong University, Jinan, China
Dawei Chen , Aiqin Gao , Wei Huang , Qian Shao , Xiangjiao Meng , Xiaoyong Tang , Pinliang Zhang , Xudong Hu , Yan Zhang , Jun Guo , Lei Fu , Wei Zhao , Changhong Zhao , Jiajia Yuan , Jinming Yu , Linlin Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04562337
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8580)
DOI
10.1200/JCO.2023.41.16_suppl.8580
Abstract #
8580
Poster Bd #
207
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2023 ASCO Annual Meeting
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.
First Author: Yun Fan
Poster
2021 ASCO Annual Meeting
Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.
First Author: Tiandong Kong
Poster
2023 ASCO Annual Meeting
A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.
First Author: Chengzhi Zhou